Ping An Biomedical Signs $2.3M Agreement To Acquire Three Oncology And Biotechnology Patents From Future Biotechnology Group

Ping An Biomedical Co., Ltd. (NASDAQ:PASW) (the "Company") today announced that it has entered into a definitive purchase agreement (the "Agreement") with Future Biotechnology Group Co., Limited for the acquisition (the "Acquisition") of three tumor cell-related medical technology patents covering areas including oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, for a consideration of US$2.3 million. The Agreement follows the Company’s previously announced letter of intent dated October 22, 2026. The Acquisition is intended to support the Company’s longer-term healthcare and biomedical R&D strategy and to establish a core intellectual property portfolio in oncology and biotechnology.

Strategic Rationale

Execution of the Agreement marks a shift from preliminary intent to a definitive contractual framework in advancing the Company’s healthcare technology. Upon completing the acquisition of the patents spanning oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, the Company seeks to strengthen its position in tumor-related science. Management views these assets as building blocks for a multi-use intellectual property portfolio—supporting proprietary programs where appropriate, while leaving room for co-development or outbound licensing if it will better serve capital efficiency.

Significance and Next Steps

With the Agreement in place, the Company’s near-term focus is to complete the closing steps and applicable registration procedures required to acquire the three patents. Upon acquisition, the Company will evaluate each patent against potential priority applications, in which process may include technical diligence, freedom-to-operate screening, and sequencing of internal pilots versus external partnerships. Any commercialization path will be staged and subject to technical, legal, regulatory and commercial evaluation and applicable approvals; the Company is not positioning the Acquisition as a near-term revenue driver, but as a capacity-building move that expands the option set for its biomedical agenda over a longer horizon. Separately, the Company continues to advance negotiations regarding its proposed strategic investment in Future Biotechnology Group Co., Limited, as previously announced.